ERBB2 and non-small cell lung carcinoma: The trial consisted of a total of 72 patients with HER2- or EGFR-positive solid tumors including BC (40%), non-small-cell lung cancer (NSCLC; 21%), ovarian cancer (8%), colorectal cancer (6%), glioblastoma (6%), renal cancer (4%), pancreatic cancer (3%), and other cancers (13%)(Chila et al. 2021; Wong et al. 2009).